Caris Life Sciences Partners with Debiopharm International SA to Develop Companion Diagnostic for Detection of Rare FGFR Fusions Using Novel Molecular Intelligence (MI) Transcriptome(TM)

Caris to develop CDx for Debiopharm's FUZE Phase II Pivotal Trial of Debio 1347 in solid tumor patients with FGFR fusions IRVING, Texas, May 30, 2019 -- (Healthcare Sales & Marketing Network) -- Caris Life Sciences®, a leading innovator in molecula... Diagnostics, Oncology Caris Life Sciences, Debiopharm, MI Transcriptome
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news